Oncogenic KRAS activates SHH production, but HH ligands do not activate the HH pathway in tumor epithelial cells in an autocrine manner (Lauthet al., 2010;Millset al., 2013;Yauchet al., 2008). Here, KRAS is linked to neoplasm.